Generate Biomedicines, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Generate Biomedicines, Inc. (GENB) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $8.24 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- Generate Biomedicines, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $8.24M, a 50.14% increase year-over-year.
- Generate Biomedicines, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $6.39M, a 34.80% increase year-over-year.
- Generate Biomedicines, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $5.49M.
- Generate Biomedicines, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-03-31 was $4.74M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month |
|---|---|---|
| 2026-06-30 | $8.24M 10-Q · filed 2026-08-06 | $14.63M derived: sum of 2 quarters · filed 2026-08-06 |
| 2026-03-31 | $6.39M 10-Q · filed 2026-08-06 | |
| 2025-06-30 | $5.49M 10-Q · filed 2026-08-06 | $10.23M derived: sum of 2 quarters · filed 2026-08-06 |
| 2025-03-31 | $4.74M 10-Q · filed 2026-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |